Aspire Capital Partners, based in Chicago, specializes in making direct investments in publicly traded companies across a broad range of industries. The firm typically engages in post-IPO equity rounds, providing innovative investment structures to companies with promising prospects that require additional capital for growth. Their investment sizes vary, with notable transactions including $20 million in Athersys and MediciNova, $25 million in Atossa Therapeutics, $15 million in Mobiquity Technologies, and $90 million in Solid Biosciences.
Aspire Capital Partners is managed by Aspire Capital Fund LLC and is known for its unique approach to fueling growth in publicly traded companies. The firm has a distinguished portfolio featuring companies like Athersys, Atossa Therapeutics, MediciNova, Mobiquity Technologies, and Solid Biosciences. Aspire Capital's investment philosophy centers on providing fair and efficient ways for companies to sell equity, ensuring they receive the necessary capital to expand and succeed in their respective markets.
Aspire Capital Partners - Portfolio Snapshot
Portfolio activity breakdown across disclosed investments and stages
Chicago-based Aspire Capital Fund LLC offers innovative investment structures, fueling growth in publicly traded companies.
Aspiro Capital Management
aspirocapital.com
Parish Capital Advisors
Health Innovation Capital
Chicago Venture Partners
chicagoventure.com
Alpha Square Group
InVivium Capital
invivium.com
Amicus Capital Partners
Rapha Capital Management
raphacap.com
Asas Capital
asascapital.com
Aspen Capital Group
aspencapgroup.com
Chicago Atlantic
Atairos.
atairos.com
Arsenal Capital Partners
arsenalcapital.com
Chicago Pacific Founders
cpfounders.com
Aspire Ventures
aspirevc.com
